Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
372 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05673057 | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 80 | Molecular Partners AGINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06428409 | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | recruiting | Phase 1 / Phase 2 | 220 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT07600749 | Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) | recruiting | Phase 1 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | recruiting | Phase 1 / Phase 2 | 474 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 23, 2026 | clinicaltrials |
| NCT05109728 | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | active not recruiting | Phase 1 | 63 | Novartis PharmaceuticalsINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT05765812 | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 116 | Debiopharm International SAINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06641908 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | recruiting | Phase 1 | 65 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT01872260 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 259 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 18, 2026 | clinicaltrials |
| NCT06780111 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 298 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Sep 17, 2026 | clinicaltrials |
| NCT07405151 | A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) | recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 17, 2026 | clinicaltrials |
| NCT06077500 | DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer(DAREONᵀᴹ-8) | active not recruiting | Phase 1 | 46 | Boehringer IngelheimINDUSTRY | 8 | Sep 16, 2026 | clinicaltrials |
| NCT06806852 | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | active not recruiting | Phase 1 | 91 | Boehringer IngelheimINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT05067283 | A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)(KANDLELIT-001) | recruiting | Phase 1 | 830 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Sep 14, 2026 | clinicaltrials |
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 460 | Bristol-Myers SquibbINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT06843447 | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | recruiting | Phase 1 / Phase 2 | 605 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Sep 11, 2026 | clinicaltrials |
| NCT04471987 | Safety and Early Signs of Efficacy of IL12-L19L19.(DODEKA) | recruiting | Phase 1 | 80 | Philogen S.p.A.INDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | active not recruiting | Phase 1 | 184 | AmgenINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation(KRAScendo 170) | recruiting | Phase 1 / Phase 2 | 320 | Hoffmann-La RocheINDUSTRY | 18 | Sep 8, 2026 | clinicaltrials |
| NCT07002320 | Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer(ASpiRE) | recruiting | Phase 1 / Phase 2 | 78 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 8, 2026 | clinicaltrials |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 1 | 41 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | recruiting | Phase 1 / Phase 2 | 210 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 3, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 2, 2026 | clinicaltrials |
| NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | active not recruiting | Phase 1 | 498 | Genentech, Inc.INDUSTRY | 17 | Aug 28, 2026 | clinicaltrials |
| NCT06596694 | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | recruiting | Phase 1 / Phase 2 | 180 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Aug 28, 2026 | clinicaltrials |
| NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Aug 27, 2026 | clinicaltrials |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 479 | AmgenINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)(DeLLphi-313) | recruiting | Phase 1 | 160 | AmgenINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT04725474 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)(GDFATHER) | active not recruiting | Phase 1 / Phase 2 | 199 | CatalYm GmbHINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT05155332 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | suspended | Phase 1 | 190 | Boehringer IngelheimINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 37 | Incyte CorporationINDUSTRY | 8 | Aug 12, 2026 | clinicaltrials |
| NCT05916313 | A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 | recruiting | Phase 1 | 20 | Boehringer IngelheimINDUSTRY | 6 | Aug 11, 2026 | clinicaltrials |
| NCT06131398 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 77 | AmgenINDUSTRY | 11 | Aug 11, 2026 | clinicaltrials |
| NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | active not recruiting | Phase 1 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Aug 7, 2026 | clinicaltrials |
| NCT00777582 | Phase I Comparative Bioavailability Study | active not recruiting | Phase 1 | 197 | AstraZenecaINDUSTRY | 4 | Aug 6, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT04058756 | Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments | active not recruiting | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 17 | Jul 28, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT05836324 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 570 | Incyte CorporationINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT05957367 | A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 94 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 291 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2026 | clinicaltrials |
| NCT05594043 | A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) | completed | Phase 1 | 39 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT06470763 | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | completed | Phase 1 / Phase 2 | 63 | Anaveon AGINDUSTRY | 7 | Jul 10, 2026 | clinicaltrials |
| NCT06217822 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)(PAnTHA) | recruiting | Phase 1 | 198 | BayerINDUSTRY | 10 | Jul 7, 2026 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials